Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
PaperCitations, authors & open-access status
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 122 citations, 2015 year and hybrid oa status.
122
Citations
2015
Year
hybrid
OA Status